Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo
礼来超预期实现销售，并规划在2026年实现大幅增长，鲜明对比诺和诺德

Eli Lilly surpassed analysts’ expectations for 2025 and fourth-quarter revenues on Wednesday morning, and anticipates a large increase in revenue this year. It marks a sharp juxtaposition to its main rival Novo Nordisk, which expects to shrink in 2026.
礼来周三早间公布的2025年及第四季度营收均超出分析师预期，并预计今年营收将大幅增长。这与其主要竞争对手诺和诺德形成鲜明对比，后者预计2026年将出现收缩。